WO2000046597A1 - Dissolution test sample holder - Google Patents
Dissolution test sample holder Download PDFInfo
- Publication number
- WO2000046597A1 WO2000046597A1 PCT/US2000/003003 US0003003W WO0046597A1 WO 2000046597 A1 WO2000046597 A1 WO 2000046597A1 US 0003003 W US0003003 W US 0003003W WO 0046597 A1 WO0046597 A1 WO 0046597A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- test sample
- membrane
- end cap
- ring
- dissolution
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/18—Apparatus therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N13/00—Investigating surface or boundary effects, e.g. wetting power; Investigating diffusion effects; Analysing materials by determining surface, boundary, or diffusion effects
- G01N2013/006—Dissolution of tablets or the like
Definitions
- This invention is a device for holding a test sample during dissolution and/or release testing and is especially suited for holding viscous topical formulations used for transdermal and dermal drug delivery.
- Topical formulations including ointments, creams, lotions, pastes, oils and gels, are used in the dermal and transdermal (through the skin) delivery of active drugs such as, for example, hydrocortisone and nitroglycerin to sites of action in the body.
- active drugs such as, for example, hydrocortisone and nitroglycerin
- Topical application of a drug is advantageous because it allows localized delivery of the therapeutic agent directly to the desired site, thus, increasing bioavailability (the extent to which a drug reaches its site of action) , reducing drug side effects and loss of therapeutic efficiency and increasing patient compliance.
- a sample of the formulation be it a cream, lotion, ointment, gel or other medium containing the drug or active agent
- a permeable membrane which simulates the barrier, presented by the skin, between the drug and the site of action.
- the membrane could be formed from actual skin taken from a laboratory animal, or a synthetic material such as polysulfone, acrylic polymer, glass fiber or PTFE to cite a few examples.
- the side of the membrane opposite the test sample is brought into contact with a liquid receptor media, and the drug or other active agent in the formulation diffuses through the membrane and dissolves into the receptor media.
- the concentration of the drug in the receptor media is measured periodically over time to establish the rate at which it is delivered into the media, thus, providing an indication of its delivery rate in actual use.
- the invention is a dissolution test sample holder immersible within a liquid for measuring the release or dissolution rate of a test sample in the liquid.
- the test sample is dispensed into the liquid by diffusion through a porous membrane mounted within the holder.
- the holder is formed by a tubular body having opposed ends, at least one of the ends being open.
- An end cap is removably attached to the open end.
- the end cap has a peripheral side wall coaxially interengaged with the body. Frictional forces between the side wall and the body hold the end cap removably to the body. An interference fit between the end cap and the body causes the friction and results in a seal between the side wall and the body.
- a flange extends substantially perpendicularly inwardly of the side wall and forms a surface within the end cap for supporting the porous membrane, the flange surrounding and defining an aperture through the end cap.
- the membrane is positionable on the surface and covers the aperture.
- the test sample is positionable within the end cap on the membrane.
- the end of the body to which the end cap is attached is immersible to bring the membrane into contact with the liquid, thereby allowing the test sample to diffuse though the porous membrane and dissolve in the liquid.
- a ring sized to fit coaxially within the end cap.
- the ring is positioned on top of the membrane, the membrane being sandwiched between the ring and the support surface.
- the ring has a predetermined thickness and an inner perimeter defining a volume holding the test sample in contact with the membrane.
- the tubular body and the end cap are cylindrical in shape
- the aperture is circular and has a predetermined diameter
- the ring has circular inner and outer perimeters.
- the ring inner diameter is substantially equal to the diameter of the aperture. This helps confine the test sample to the wetted area of the membrane, thus, ensuring that all of the sample is available for dissolution into the liquid. Varying the ring inner diameter as well as the ring thickness allows the volume of the test sample to be controlled as desired within the size limits of the end cap and body. In order to provide a membrane support surface of practical size, the end cap aperture diameter is smaller than an inner diameter of the body.
- the test sample holder Due to its construction, the test sample holder according to the invention allows the test sample to be loaded after the holder has been assembled. This provides an opportunity to visually inspect the loaded holder and ensure that the correct amount of sample has been loaded, that there are no air bubbles or other voids in the sample diminishing the membrane wetted surface and that the membrane has not been damaged by the assembly or loading of the holder.
- a sample cover is used.
- the sample cover is formed by a disk having a diameter sized to slidingly interfit coaxially within the body and seat on the ring. When seated, the disk covers the test sample held within the inner perimeter of the ring.
- Agitation is provided by having an opening in the body at the opposite end from the end cap, the opening being sized to accept a rotatable shaft in frictional interengagement .
- the shaft is coaxial with the body and rotates it with the end cap end immersed within the liquid to promote dissolution of the test sample into the liquid.
- the invention is used in a method of dissolution and/or release testing of a test sample in a liquid.
- the method comprises the steps of:
- end cap removably attachable to one of the ends, the end cap having a peripheral side wall coaxially interengagable with the body and a flange extending substantially perpendicularly inwardly of the side wall and forming a support surface within the end cap, the flange surrounding and defining an aperture through the end cap; (c) providing a porous membrane positionable within the end cap on the support surface and covering the aperture;
- the method When necessitated by the use of a thin or delicate membrane, the method also includes the steps of:
- the loading step comprises loading the test sample onto the membrane within the inner perimeter of the ring.
- test sample holder wherein the test sample can be visually inspected after the holder has been assembled and the test sample has been loaded.
- test sample holder which can be rotated to provide agitation to promote the dissolution of the test sample. It is again another object of the invention to provide a test sample holder which can be used with standard dissolution equipment and procedures as specified in the United States Pharmacopeia.
- Figure 1 is an exploded perspective view of a test sample holder according to the invention
- Figure 2 is a cross sectional side view of the test sample holder shown in Figure 1, the holder being shown assembled and on an enlarged scale;
- Figure 3 is a side view of the test sample holder shown in Figures 1 and 2 in operation, Figure 3 being on a reduced scale;
- Figure 4 is a flow chart describing a method for dissolution testing according to the invention.
- Figure 1 shows an exploded isometric view of an in vitro dissolution test sample holder 10 according to the invention.
- Sample holder 10 comprises a tubular body 12 having opposed open ends 14 and 16, a ring 18 and an end cap 20.
- End cap 20 has a peripheral side wall 22 coaxially interengagable with the body 12 at open end 14 , and a flange 24 which extends substantially perpendicularly inwardly to define an aperture 26 through the end of the end cap. Cylindrical and circular shapes for the body, ring, end cap and apertures are preferred for ease of manufacture and assembly of the holder 10.
- Flange 24 forms a support surface 28 within the end cap to support a porous membrane 30 which is placed within the end cap in overlying relation covering aperture 26.
- the diameter of aperture 26 is smaller than the inner diameter of body 12 to provide a membrane support surface of practical size.
- Ring 18 interfits coaxially within end cap 20 on top of membrane 30, the membrane being sandwiched between ring 18 and support surface 28 as seen in the cross- sectional view of Figure 2.
- Synthetic membranes having pore sizes on the order of 0.45 microns have been found useful in dissolution testing although membranes of natural material, such as skin harvested from laboratory animals are also contemplated.
- End cap 20 removably interengages tubular body 12, the end cap being retained to the tubular body, preferably by a friction or interference fit between the peripheral side wall 22 and the tubular body. It is preferred to have end cap 20 receive the body 12 as shown in Figure 2 allowing the cap to be manually gripped and easily removed from the body.
- the frictional interengagement between side wall 22 and body 12 forms a seal keeping liquid receptor media out of the body when the holder is immersed as described below. Frictional interengagement of the end cap and the body eliminates the need for 0-rings and other types of seals, thus, simplifying the design of the holder.
- the tubular body has an end surface 32 at open end 14 which engages ring 18 and compresses it against the membrane 30.
- the membrane is, thus, clamped between flange 24 and ring 18 by the compressive force between the end cap and the tubular body.
- Ring 18 has an inner perimeter 34 which is preferably sized and shaped to match the size and shape of aperture 26 as shown in Figure 2.
- the ring also has a predetermined thickness 36. As best seen in Figure 2, the thickness 36 and perimeter 34 define a sample holding volume 38 where a sample 40 of the formulation to be tested is placed.
- sample cover 42 is provided to prevent the sample from evaporating and leaving a residue during testing. Evaporation is a concern for example, during dissolution testing at elevated temperatures, or during tests of long duration.
- sample cover 42 comprises a disk 44 which is sized and shaped to easily fit coaxially within tubular body 12 and seat on top of ring 18 completely covering the holding volume 38.
- the sample cover has a handle 46 to facilitate manual placing of the sample cover into the tubular body.
- Figure 4 is a flow chart which describes a method of dissolution testing according to the invention. Briefly described, the method steps include providing the various components comprising the test sample holder, assembling the components, loading the membrane with the test sample, mounting the holder on a rotatable shaft, immersing the end cap into a receptor media, agitating the media by rotating the holder, periodically measuring the concentration of the test sample in the receptor media and determining the rate of dissolution or drug release from the concentration measurements. These steps are described in more detail below.
- the membrane 30 is placed within end cap 20 on support surface 28 completely covering aperture 26. Ring 18 is then placed within end cap 20 on membrane 30.
- the end cap is interengaged with the open end 14 of tubular body 12, the peripheral side wall 22 receiving and engaging the tubular body 12 forming a seal and the tubular body end surface 32 engaging and compressing ring 18 against the membrane.
- Sample material 40 is then loaded into the holding volume 38 through the opposite open end 16 of body 12.
- the sample may be visually checked through open end 16 of body 12 to ensure that it completely covers the portion of membrane 30 beneath the holding volume 38 without any air pockets or other voids.
- the sample cover 42 is placed within the tubular body 12 after visual inspection. The sample cover seats against ring 18 and prevents evaporation of the sample during the test.
- the assembled sample holder 10, loaded with test sample material 40 is mounted on the end of a shaft 48 which is rotatably mounted on an armature 50 shown in Figure 3.
- armature 50 shown in Figure 3.
- open end 16 of body 12 receives the shaft, the shaft and the body interfitting in a friction or interference fit which retains the body to the shaft, yet allows it to be easily manually removed without the need for tools and separate fasteners. This affords a simple design, which is easy to use and requires few parts.
- the sample holder 10 is mounted on the end of rotatable shaft 48 and positioned with end cap 20 immersed in a liquid receptor media 52 contained within a vessel 54.
- Vessel 54 is itself immersed in a liquid bath 56 used to control the temperature of the receptor media 52.
- receptor media 52 is a phosphate buffered aqueous solution having a pH which is set to simulate the conditions under which the sample will be used to dermally and/or transdermally deliver a drug or other therapeutic agent.
- Aperture 26 (see Figure 2) exposes the side 30a of membrane 30 opposite the sample material 40 to the receptor media 52.
- sample holder 10 can be rotated on shaft 48 by armature 50 at a predetermined rate to agitate the receptor media and further promote dissolution by maintaining sink conditions.
- the concentration of the drug or therapeutic agent in the media is measured.
- the dissolution or drug release rate is then determined from these concentration measurements.
- One method of determining the rate is by generating a curve depicting the functional relation of concentration versus time from these measurements, the slope of the curve providing the dissolution rate of the sample.
- the volume of the receptor media 52 is sufficiently large to keep the receptor media in a sink condition, i.e., always having a very low concentration of the active agent so as not to affect the dissolution or release rate of the sample.
- the sample holder 10 is made of a chemically stable material such as Teflon® (PTFE) , stainless steel or titanium so that it will not react with the sample material or the receptor media and adversely affect the dissolution testing. It is advantageous to fabricate all of the components from the same material so that all of the parts have the same coefficient of thermal expansion. This will ensure that the parts fit together in the same relationship and maintain friction fits regardless of the temperature of the sample holder. If stainless steel or titanium is used, it is desirable to coat any points of contact between parts with Teflon® to facilitate assembly of the parts by allowing them to slide easily over one another.
- PTFE Teflon®
- Arranging the sample holder with the membrane 30 at the bottom ensures that the sample material 40 will be in contact with the membrane during the testing and, thus, be available to diffuse through the membrane and dissolve in the receptor media 52. It is expected that this configuration will provide for accurate, reproducible test results with a minimum of undesired variability between tests. This is especially important for testing lotions or oils which have a relatively low viscosity as compared with creams, gels or pastes. Lotions or oils would tend to run and separate from the membrane if the sample holder were in any other orientation. Thus, not all of the sample would be available for dissolving in the receptor media, adversely affecting the test results.
- the use of the ring 18 to hold the membrane 30 in place provides a distinct advantage over other sample holders by allowing the sample holder according to the invention to be easily assembled without damaging the membrane.
- Membranes tend to be delicate and easily torn, wrinkled or punctured when inserted into the sample holder. It is especially difficult to assemble sample holders in which the membrane is clamped between two parts which move relatively to one another, such as a screw cap on the end of a cylinder.
- sample holder is completely assembled before any sample is introduced into it. This allows the sample material 40 to be visually inspected after it is placed in the sample holding volume 38 to ensure that the material is in contact with the entire membrane beneath the holding volume, and there are no air bubbles trapped against the membrane forming an occlusion. This is unlike other sample holders in which the sample material is placed into a part of the holder which is then joined to another part, effectively blocking all access to the sample material. Allowing visual inspection of the sample material prior to the test will help ensure accurate and repeatable test results with variability reduced to a minimum.
- the in vitro test sample holder according to the invention is expected to provide an improved device for dissolution testing of topical formulations for the dermal and/or transdermal delivery of drugs or other therapeutic agents. Its configuration and construction are specifically designed to avoid the problems and disadvantages associated with devices currently used for dissolution and/or release testing and should result in more accurate and reliable test results.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Physics & Mathematics (AREA)
- Water Supply & Treatment (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU38562/00A AU3856200A (en) | 1999-02-05 | 2000-02-04 | Dissolution test sample holder |
US09/890,484 US6929782B1 (en) | 1999-02-05 | 2000-02-04 | Dissolution test sample holder |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11882799P | 1999-02-05 | 1999-02-05 | |
US60/118,827 | 1999-02-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000046597A1 true WO2000046597A1 (en) | 2000-08-10 |
WO2000046597A9 WO2000046597A9 (en) | 2001-07-26 |
Family
ID=22380974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/003003 WO2000046597A1 (en) | 1999-02-05 | 2000-02-04 | Dissolution test sample holder |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3856200A (en) |
WO (1) | WO2000046597A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1455187A1 (en) * | 2003-03-05 | 2004-09-08 | Labonord | Device for filtering and transfering particles |
WO2006047076A1 (en) * | 2004-10-21 | 2006-05-04 | Cytyc Corporation | Reduced aperture biological specimen collection and transfer device |
US9733254B2 (en) | 2012-10-04 | 2017-08-15 | The University Of Bath | Methods and apparatus for the in vitro modelling of drug administration |
WO2021093979A1 (en) * | 2019-11-15 | 2021-05-20 | Nanopharm Limited | In vitro release testing (ivrt) device for orally inhaled drug products |
US20210247287A1 (en) * | 2020-02-12 | 2021-08-12 | National Guard Health Affairs | In vitro dissolution test method for fluticasone propionate and other inhaled drugs |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3801280A (en) * | 1971-11-11 | 1974-04-02 | Upjohn Co | Solubility-dissolution test apparatus and method |
US3802272A (en) * | 1973-01-24 | 1974-04-09 | Dow Chemical Co | Automatic dissolution rate determinator |
US4464340A (en) * | 1981-06-15 | 1984-08-07 | Burroughs Wellcome Co. | Dissolution flask |
US4578244A (en) * | 1982-04-23 | 1986-03-25 | Pharmacontrol Corp. | Sampling apparatus for obtaining a plurality of fluid samples |
US4856909A (en) * | 1986-06-23 | 1989-08-15 | Rorer Pharmaceutical Corporation | Pharmacological dissolution method and apparatus |
US5011662A (en) * | 1983-03-04 | 1991-04-30 | Akbar Noormohammadi | Dissolution testing machine |
US5108710A (en) * | 1990-11-26 | 1992-04-28 | Little Amy C | Transdermal patch holder |
US5407567A (en) * | 1993-11-01 | 1995-04-18 | Newhard; Harry W. | Compartmentalized swimming pool chemical dispenser |
US5412979A (en) * | 1993-05-03 | 1995-05-09 | Temple University - Of The Commonwealth System Of Higher Education | Method and apparatus for dissolution testing of a dosage form |
US5476116A (en) * | 1994-10-18 | 1995-12-19 | Rainbow Lifegard Products, Inc. | Floating adjustable pool chlorinator |
US5589649A (en) * | 1994-02-25 | 1996-12-31 | Distek, Inc. | Dissolution testing apparatus |
US5816701A (en) * | 1996-04-22 | 1998-10-06 | Source For Automation, Inc. | Automated tablet dissolution apparatus |
-
2000
- 2000-02-04 AU AU38562/00A patent/AU3856200A/en not_active Abandoned
- 2000-02-04 WO PCT/US2000/003003 patent/WO2000046597A1/en active Application Filing
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3801280A (en) * | 1971-11-11 | 1974-04-02 | Upjohn Co | Solubility-dissolution test apparatus and method |
US3802272A (en) * | 1973-01-24 | 1974-04-09 | Dow Chemical Co | Automatic dissolution rate determinator |
US4464340A (en) * | 1981-06-15 | 1984-08-07 | Burroughs Wellcome Co. | Dissolution flask |
US4578244A (en) * | 1982-04-23 | 1986-03-25 | Pharmacontrol Corp. | Sampling apparatus for obtaining a plurality of fluid samples |
US5011662A (en) * | 1983-03-04 | 1991-04-30 | Akbar Noormohammadi | Dissolution testing machine |
US4856909A (en) * | 1986-06-23 | 1989-08-15 | Rorer Pharmaceutical Corporation | Pharmacological dissolution method and apparatus |
US5108710A (en) * | 1990-11-26 | 1992-04-28 | Little Amy C | Transdermal patch holder |
US5412979A (en) * | 1993-05-03 | 1995-05-09 | Temple University - Of The Commonwealth System Of Higher Education | Method and apparatus for dissolution testing of a dosage form |
US5407567A (en) * | 1993-11-01 | 1995-04-18 | Newhard; Harry W. | Compartmentalized swimming pool chemical dispenser |
US5589649A (en) * | 1994-02-25 | 1996-12-31 | Distek, Inc. | Dissolution testing apparatus |
US5476116A (en) * | 1994-10-18 | 1995-12-19 | Rainbow Lifegard Products, Inc. | Floating adjustable pool chlorinator |
US5816701A (en) * | 1996-04-22 | 1998-10-06 | Source For Automation, Inc. | Automated tablet dissolution apparatus |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1455187A1 (en) * | 2003-03-05 | 2004-09-08 | Labonord | Device for filtering and transfering particles |
WO2006047076A1 (en) * | 2004-10-21 | 2006-05-04 | Cytyc Corporation | Reduced aperture biological specimen collection and transfer device |
US7507578B2 (en) | 2004-10-21 | 2009-03-24 | Cytyc Corporation | Reduced aperture biological specimen collection and transfer device |
US9733254B2 (en) | 2012-10-04 | 2017-08-15 | The University Of Bath | Methods and apparatus for the in vitro modelling of drug administration |
WO2021093979A1 (en) * | 2019-11-15 | 2021-05-20 | Nanopharm Limited | In vitro release testing (ivrt) device for orally inhaled drug products |
CN114868019A (en) * | 2019-11-15 | 2022-08-05 | 纳米制药有限公司 | In Vitro Release Testing (IVRT) device for oral inhalation of pharmaceutical products |
JP2023509570A (en) * | 2019-11-15 | 2023-03-09 | ナノファーム リミテッド | In Vitro Release Testing (IVRT) Device for Oral Inhalation Formulations |
JP7427781B2 (en) | 2019-11-15 | 2024-02-05 | ナノファーム リミテッド | In vitro release testing (IVRT) device for oral inhalation formulations |
US12078628B2 (en) | 2019-11-15 | 2024-09-03 | Nanopharm Limited | In vitro release testing (IVRT) device for orally inhaled drug products |
US20210247287A1 (en) * | 2020-02-12 | 2021-08-12 | National Guard Health Affairs | In vitro dissolution test method for fluticasone propionate and other inhaled drugs |
US11499904B2 (en) * | 2020-02-12 | 2022-11-15 | National Guard Health Affairs | In vitro dissolution test method for fluticasone propionate and other inhaled drugs |
Also Published As
Publication number | Publication date |
---|---|
AU3856200A (en) | 2000-08-25 |
WO2000046597A9 (en) | 2001-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6929782B1 (en) | Dissolution test sample holder | |
US4594884A (en) | Diffusion measuring device | |
Friend | In vitro skin permeation techniques | |
Olejnik et al. | Active compounds release from semisolid dosage forms | |
US4667504A (en) | Flow through device for determination of the penetration rate of chemicals across biological membranes in vitro | |
JP2002514755A (en) | Cartridge for electrochemical analysis | |
US20060260421A1 (en) | Dissolution tester | |
ZA200508728B (en) | Static diffusion cell for diffusion sampling systems | |
JP2011502623A (en) | Transdermal body fluid sampling and pretreatment apparatus and method | |
US20060207356A1 (en) | Dosage form holder device and methods for immersion testing | |
JP2011506934A (en) | Dissolution test apparatus and method for testing | |
JP6763400B2 (en) | Toilet bowl, method for measuring components in stool sample, method for stabilizing components in stool sample, and method for storing stool sample | |
EP2251691A1 (en) | Method for analyzing sample solution and apparatus for analyzing sample solution | |
WO2000046597A1 (en) | Dissolution test sample holder | |
US8647295B2 (en) | Method for use of microdialysis | |
US10613011B2 (en) | Diffusion cells and related methods | |
JP3349248B2 (en) | Flow type corneal permeation test equipment and experimental equipment using this test equipment | |
JPS6073346A (en) | Method and device for measuring speed of dissolution | |
Jug et al. | In vitro dissolution/release methods for mucosal delivery systems | |
US4798207A (en) | Device for enabling time-integrated measurement of substances in biological fluids | |
KR20010006499A (en) | Method and device for determining adhesive performance of flat adhesive products on the skin of humans or mammals | |
KR101781741B1 (en) | Test apparatus for material diffusion and the test method using thereof | |
US20020143244A1 (en) | In-vivo blood storage system | |
WO1990015995A1 (en) | Method and apparatus for the determination of glycosylated protein | |
EP3295167B1 (en) | Method for determining release rates of active principle ingredients from at least one semisolid form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/3-3/3, DRAWINGS, REPLACED BY NEW PAGES 1/3-3/3; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09890484 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |